Last reviewed · How we verify

Pradaxa — Competitive Intelligence Brief

Pradaxa (dabigatran etexilate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct oral anticoagulant (DOAC) — direct thrombin inhibitor. Area: Cardiovascular.

marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pradaxa (dabigatran etexilate) — Generic (originally Boehringer Ingelheim). Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pradaxa TARGET dabigatran etexilate Generic (originally Boehringer Ingelheim) marketed Direct oral anticoagulant (DOAC) — direct thrombin inhibitor Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone] 2010-10-19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct oral anticoagulant (DOAC) — direct thrombin inhibitor class)

  1. Generic (originally Boehringer Ingelheim) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pradaxa — Competitive Intelligence Brief. https://druglandscape.com/ci/dabigatran. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: